Marco Meglio

The revision accounts for data from the NURTURE trial showing that patients with 3 copies of SMN2 greatly benefit from early treatment.

Patients with Huntington disease who received antihypertensive medication had slower disease progression less cognitive impairment compared with patients with untreated hypertension.

The DWI-based hierarchic algorithm predicted the risk of disability at 3 months for up to 100% of patients with a high predictive value.

The Nippon Shinyaku investigational DMD agent has a Prescription Drug User Fee Act date within the third quarter of 2020.

When compared with placebo, prophylactic pharmacologic treatments showed no significant long-term effects in pediatric patients with migraine.

Stress coping abilities may have a direct impact on the early accumulation of tau pathology.

Presurgical counseling can be improved by better understanding seizure outcomes associated with different surgery locations, pathologies, nonlesional epilepsy, and incomplete resections.

William O. Tatum, DO, discussed the additive value of smartphone video technology in diagnosing epilepsy.

Additional analysis of secondary endpoints and biomarkers are expected to be presented at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting in April 2020.

The antioxidants adiponectin, total radical-trapping antioxidant parameter, sulfhydryl groups, zinc, and soluble tumor necrosis factor receptor 2 all play a role in the pathophysiology of multiple sclerosis.

The biotech company plans to roll out 2 clinical trials for patients with amyotrophic lateral sclerosis following the orphan drug designation for PrimeC.

Recently published data showed that one-quarter of the smartphone videos were correctly diagnosed by 100% of the reviewing physicians.

Mean arterial blood pressure may be a barometer for poor neurologic outcomes in patients with acute ischemic stroke who undergo endovascular therapy.

Interim analysis compared ataluren in a real-world setting from the STRIDE registry with a matched cohort; the final data from the STRIDE registry are expected in 2025.

The drug was previously indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Interim analysis compared ataluren in a real-world setting from the STRIDE registry with a matched cohort; the final data from the STRIDE registry are expected in 2025.

The drug will be available in 50 mg and 100 mg oral tablets in pharmacies across the US in the coming days.

The previously approved therapy is now indicated for treatment in pediatric patients age 2 to 10.

Page B. Pennell, MD, president of the American Epilepsy Society, shared her thoughts on the epilepsy treatment landscape, managing women with epilepsy, and the need for multidisciplinary involvement and communication.

The unique CDKL5 deficiency disorder diagnostic code will be incorporated in the October 1, 2020 classification revision.

Teva announced that the Ajovy autoinjector is expected to be available to patients in the coming months.

Seizure-free patients experienced similar rates of graduation and employment following epilepsy surgery compared to the general population.

Those taking the drug achieved a significant reduction in the risk of stroke and death after acute ischemic stroke or transient ischemic attack when coupling it with aspirin.

Findings from a study revealed that 50% of strokes in adolescents remained cryptogenic, sparking the need for multidisciplinary collaboration on prevention and management.

The phase 2 clinical trial of CAD-1883 will assess the efficacy and safety of the drug compared to placebo.

Caregivers who care for children with frequent seizures experienced the greatest economic deficit, begging the question whether epilepsy interventions should be weighed based on cost/benefit.

The first trial of its kind in amyotrophic lateral sclerosis will first examine 3 drugs and add additional treatments as more become available.

The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.

Findings from the small-scale study showed that the drug had target engagement with β-glucocerebrosidase as well as cerebrospinal fluid penetration.

Findings from a large scale analysis show higher rates of cognitive impairment and neuropsychiatric disturbances in patients with parkinsonism-dominant motor-manifest individuals.